Post-Treatment Outcomes in a Double-Blind, Randomized Trial of Sertraline for Alcohol Dependence

Alcoholism: Clinical and Experimental Research

Volumn 36, Issue 4, 2012, Pages 739-744

  Kranzler, Henry R ^a,b   Armeli, Stephen ^c   Tennen, Howard ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c FAIRLEIGH DICKINSON UNIVERSITY   (United States)

^d UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

5 HTTLPR; Age of Onset; Alcohol Dependence; Post Treatment Outcomes; Selective Serotonin Reuptake Inhibitor

Indexed keywords

PLACEBO; SERTRALINE;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; AGED; ALCOHOLISM; ALLELES; DATA INTERPRETATION, STATISTICAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; GENOTYPE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 84859187745     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2011.01659.x     Document Type: Article

References (21)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th edn. American Psychiatric Association, Washington, DC.
2. Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, Rounsaville B (1992) Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry49:599-608.
3. Chick J, Aschauer H, Hornik K, Investigators' Group (2004) Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend74:61-70.
4. Cloninger CR (1987) Neurogenetic adaptive mechanisms in alcoholism. Science236:410-416.
5. Dundon W, Lynch KG, Pettinati HM, Lipkin C (2004) Treatment outcomes in type A and B alcohol dependence 6months after serotonergic pharmacotherapy. Alcohol Clin Exp Res28:1065-1073.
6. First M, Spitzer R, Gibbon M (2001) Structured Clinical Interview for DSM-IC-TR Axis I Disorders, Research Version. Patient Edition with Psychotic Screen (SCID-I/P W/PSYSCREEN). Biometric Research, New York State Psychiatric Institute, New York.
7. Hu X, Oroszi G, Chun J, Smith TL, Goldman D, Schuckit MA (2005) An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol Clin Exp Res29:8-16.
8. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, Murphy DL, Goldman D (2006) Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet78:815-826.
9. Kranzler HR, Abu-Hasaballah K, Tennen H, Feinn R, Young K (2004) Using daily interactive voice response technology to measure drinking and related behaviors in a pharmacotherapy study. Alcohol Clin Exp Res28:1060-1064.
10. Kranzler HR, Armeli S, Tennen H, Covault J, Feinn R, Arias AJ, Pettinati H, Oncken C (2011) A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol31:22-30.
11. Kranzler HR, Burleson JA, Brown J, Babor TF (1996) Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res20:1534-1541.
12. Kranzler HR, Ciraulo D, Jaffe JH (2009) Medications for use in alcohol rehabilitation, in Principles of Addiction Medicine, 4th ed (Ries R, Fiellin D, Miller S, Saitz R eds), pp 6311-6344. Lippincott, Williams, and Wilkins, Baltimore.
13. Kranzler HR, Feinn R, Armeli S, Tennen H (in press) Comparison of alcoholism subtypes as moderators of the response to sertraline treatment. Alcohol Clin Exp Res doi: 10.1111/j.1530-0277.2011.01609.x [Epub ahead of print].
14. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science274:1527-1531.
15. Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP (2008) Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Inf J42:303-319.
16. Miller W, Tonigan J, Longabaugh R (1995) The Drinker Inventory of Consequences (DrInC): an instrument for assessing adverse consequences of alcohol abuse, in NIAAA Project MATCH Monograph Series Volume 4 (DHHS Publication No. 95-3911). National Institute on Alcohol Abuse and Alcoholism, Rockville.
17. Nakamura M, Ueno S, Sano A, Tanabe H (2000) The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry5:32-38.
18. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A (2000) Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res24:1041-1049.
19. Prakash A, Risser RC, Mallinckrodt CH (2008) The impact of analytic method on interpretation of outcomes in longitudinal clinical trials. Int J Clin Pract62:1147-1158.
20. Singer JD, Willett JB (2003) Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. Oxford University Press, New York.
21. Sobell L, Sobell M (1992) Timeline follow-back: a technique for assessing self-reported alcohol consumption, in Measuring Alcohol Consumption (Litten R, Allen J eds), pp 41-72. Humana Press, Clifton.